An engineered immunocytokine with collagen affinity improves the tumor bioavailability, tolerability, and therapeutic efficacy of IL-2

Silver, Aliyah B.; Tzeng, Stephany Y.; Lager, Mallory; Wang, Jeremy; Ishihara, Jun; Green, Jordan J.; Spangler, Jamie B.

doi:10.1016/j.xcrm.2023.101289

Cited by 1 publication

(2 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To overcome these limitations, our lab developed intramolecularly assembled cytokine/antibody fusion proteins (immunocytokines, ICs) that fuse IL-2 to the N-terminus of the F10 and F5111 antibody light chains. These engineered ICs (denoted F10 IC and F5111 IC) selectively bias the effects of IL-2 and prolong cytokine half-life in serum, and they show encouraging preclinical promise as molecular therapeutics to treat cancer or autoimmune conditions (Leonard et al, 2023;Silver et al, 2023;VanDyke et al, 2022).…”

Section: Introductionmentioning

confidence: 99%

“…Subsequent studies have identified anti‐human IL‐2 analogs of both S4B6 and JES6‐1, denoted MAB602 (Krieg et al., 2010; Létourneau et al., 2010) and F5111 (Trotta et al., 2018), respectively. Subsequent protein engineering efforts developed the F10 antibody as a more immune effector cell‐biased iteration of MAB602 (Silver et al., 2023; VanDyke et al., 2022). Although the anti‐human IL‐2 antibodies F10 and F5111 were shown to therapeutically bias cytokine function (Krieg et al., 2010; Létourneau et al., 2010; Trotta et al., 2018), translation of non‐covalent cytokine/antibody complexes faces several challenges.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Cytokine/Antibody Fusion Protein Design and Evaluation

Fabilane,

Stephenson,

Leonard

et al. 2024

Current Protocols

Self Cite

View full text Add to dashboard Cite

Cytokines constitute a class of secreted proteins that activate transmembrane receptors to coordinate a vast array of physiological processes, particularly those related to immune activity. Due to their vital role in immune regulation, cytokines have garnered great interest as potential therapeutic agents. Unfortunately, the clinical success of cytokine drugs has been limited by their multifunctional activities, which hinder therapeutic performance and lead to harmful toxicities. In addition, the strikingly short circulation half‐life of cytokines further hampers their efficacy as drugs. To overcome the translational challenges associated with natural cytokines, significant efforts have focused on engineering cytokines to target their activities and improve their pharmacological properties. One such strategy is the design of fusion proteins that tether a cytokine to an anti‐cytokine antibody that selectively biases its functions and extends its serum half‐life. These cytokine/antibody fusion proteins (termed immunocytokines) assemble intramolecularly to bias cytokine signaling behavior through multi‐layered structural and molecular effects. Here, we present a detailed workflow for the design, production, and functional validation of intramolecularly assembled immunocytokines. In‐depth procedures are presented for gene manipulation, mammalian cell‐based expression and purification, binding analysis via bio‐layer interferometry, and interrogation of cytokine signaling activity on human primary cells. In contrast with immunocytokines in which the tethered cytokine and antibody do not bind one another, intramolecularly assembled immunocytokines require special considerations with respect to their production to avoid oligomerization and/or aggregation. The protocol herein was developed based on experience with immunocytokines that incorporate interleukin‐2 (IL‐2); however, this modular approach can be extended to any cytokine of interest for a broad range of biomedical applications. © 2024 Wiley Periodicals LLC.Basic Protocol 1: Design and generation of immunocytokine genesBasic Protocol 2: Immunocytokine expression and purificationBasic Protocol 3: Validation of immunocytokine assembly and binding by bio‐layer interferometryBasic Protocol 4: Analysis of immunocytokine signaling on human primary cells

show abstract

Section: Introductionmentioning

confidence: 99%